Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Amlodipine/Valsartan [Design Issues]

posted by Bebac user – Egypt, 2023-09-09 08:34 (1008 d 16:01 ago) – Posting: # 23713
Views: 7,407

The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated ?

Complete thread:

Amlodipine/ValsartanBebac user 2023-09-09 06:34
- Amlodipine/Valsartan Helmut 2023-09-12 06:48
  - Amlodipine/Valsartan Kumarnaidu2 2023-12-06 09:36
    - Amlodipine/Valsartan dshah 2023-12-06 16:49
      - Amlodipine/Valsartan Kumarnaidu2 2023-12-07 02:42
    - Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 09:01

Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
130 visitors (0 registered, 130 guests [including 31 identified bots]).
Forum time: 00:35 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking. Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz